gefitinib has been researched along with Papillomavirus Infections in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aderhold, C; Birk, R; Huber, L; Kramer, B; Mueller, CE; Rotter, N; Schell, A | 1 |
| Bellini, A; Carey, TE; Chiocca, S; Citro, S; Ghiani, L; Miccolo, C | 1 |
| Han, F; Liu, W; Liu, Y; Miao, Q; Su, Y; Sun, M; Tian, H; Zhao, Y | 1 |
| Arora, H; Biswas, S; Gandhi, G; Naseem, A; Perwez, A; Qureshi, R; Rizvi, MA; Wajid, S | 1 |
| Aikou, T; Akiba, S; Baba, M; Castillo, A; Eizuru, Y; Higashi, M; Itoh, T; Khan, N; Koriyama, C; Matsumoto, H; Natsugoe, S; Shuyama, KY; Yanagi, M | 1 |
| Bostrom, B; Drehner, D; Lander, T; Marker, S; Sidman, J | 1 |
1 review(s) available for gefitinib and Papillomavirus Infections
| Article | Year |
|---|---|
Impact of age on the overall survival benefits of anti-EGFR-containing regimens in head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Cetuximab; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Panitumumab; Papillomavirus Infections; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck | 2019 |
5 other study(ies) available for gefitinib and Papillomavirus Infections
| Article | Year |
|---|---|
Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Everolimus; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Papillomavirus Infections; Protein Kinase Inhibitors; Pyrimidines; Receptor, IGF Type 1; Squamous Cell Carcinoma of Head and Neck | 2020 |
Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Gefitinib; Histone Deacetylase Inhibitors; Humans; Papillomaviridae; Papillomavirus Infections; Protein Kinase Inhibitors; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Transcription Factors; Tumor Suppressor Proteins; Vorinostat | 2019 |
Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; HeLa Cells; Human papillomavirus 16; Human papillomavirus 18; Humans; India; Middle Aged; Mutation; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Uterine Cervical Neoplasms | 2016 |
Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p16; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Papillomaviridae; Papillomavirus Infections; Prevalence; Quinazolines; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53 | 2010 |
Gefitinib therapy for life-threatening laryngeal papillomatosis.
Topics: Adolescent; Antiviral Agents; Bronchoscopy; ErbB Receptors; Gefitinib; Humans; Laryngeal Neoplasms; Male; Papilloma; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Recurrence; Treatment Outcome | 2005 |